Imunon shares jump 10.06% intraday after announcing $7 million registered direct offering to fund corporate purposes.

Imunon (IMNN) surged 10.06% intraday following the announcement of a $7.0 million registered direct offering. The company entered a Securities Purchase Agreement with an undisclosed healthcare-focused institutional investor, issuing shares and warrants at $3.61 per unit. The proceeds will fund R&D, capital expenditures, and working capital, addressing operational needs and growth initiatives. The immediate exercisability of warrants and the non-expiring nature of pre-funded warrants added liquidity appeal, likely boosting investor confidence. The transaction, disclosed in a Dec. 31, 2025 SEC filing, aligns with market optimism over the firm’s capital-raising strategy and corporate development prospects.